Intrathecal Transplantation of UC-MSC in Patients With Sub-Acute Spinal Cord Injury
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study aim to evaluate the safety and efficacy of intrathecal transplantation of
allogeneic umbilical cord derived mesenchymal stem cells (UC-MSC) for treatment of different
phrases of spinal cord injury. Here, the history of spinal cord injury is divided into three
periods, Sub-acute SCI, Early stage of chronic SCI, and Late stage of chronic SCI, which is
2W-2M, 2M-12M, and more than 12M after injury, respectively. The purpose is to investigate
whether the patients with spinal cord injury benefit from UC-MSC transplantation, and then
find out the best time for SCI treatment.
In this part of the study, the investigators will treat patients with sub-acute spinal cord
injury with UC-MSC transplantation or placebo.